# Liver Biopsy Interpretation

## Overview

Liver biopsy remains the gold standard for characterizing hepatic parenchymal disease, despite the growing role of non-invasive assessment methods. A systematic approach integrating pattern recognition with clinical context is essential for accurate diagnosis. The major patterns of injury include hepatitic, cholestatic, steatotic, vascular, and mass lesion categories.

## Adequacy and Processing

An adequate liver biopsy core measures at least 15 mm in length and contains 11 or more complete portal tracts for the evaluation of diffuse disease. Fragmented cores or those shorter than 10 mm may lead to sampling error, particularly when staging fibrosis. The standard stain panel includes H&E, trichrome (for fibrosis assessment), reticulin (for architecture), iron stain (Perls Prussian blue), PAS-diastase (for alpha-1-antitrypsin globules and ceroid), and rhodanine or orcein (for copper).

## Pattern-Based Approach to Liver Injury

### Hepatitic Pattern

The hepatitic pattern is characterized by portal and/or lobular inflammation with hepatocyte injury. Interface hepatitis refers to a lymphocytic infiltrate extending from the portal tract into periportal hepatocytes (piecemeal necrosis) and is the hallmark of autoimmune hepatitis and chronic viral hepatitis. Lobular hepatitis shows scattered hepatocyte necrosis with an inflammatory infiltrate distributed throughout the lobules. Confluent or bridging necrosis consists of bands of necrosis connecting portal-to-portal or portal-to-central zones and indicates severe disease.

### Cholestatic Pattern

Hepatocanalicular cholestasis presents as bile plugs within dilated canaliculi, predominantly in the centrilobular zone. Ductular reaction refers to proliferation of small ductules at the portal-periportal interface. Large duct obstruction produces portal edema, ductular reaction, periductal neutrophils, bile duct changes, and bile lakes. Small duct (vanishing bile duct) diseases include primary biliary cholangitis, primary sclerosing cholangitis, drug reactions, and other causes of ductopenia.

### Steatotic Pattern

Macrovesicular steatosis features large single fat droplets displacing the nucleus and is associated with metabolic syndrome, alcohol use, and various drugs. Microvesicular steatosis shows multiple small fat droplets with a central nucleus and is associated with acute fatty liver of pregnancy, Reye syndrome, valproate toxicity, and mitochondrial dysfunction. The microvesicular pattern is more clinically ominous.

### Vascular Pattern

Vascular injury manifests as sinusoidal congestion, centrilobular hemorrhagic necrosis, and peliosis. Causes include Budd-Chiari syndrome, heart failure, and sinusoidal obstruction syndrome (veno-occlusive disease).

## Steatotic Liver Disease (Formerly NAFLD/NASH)

### Nomenclature Update

The nomenclature has been updated: NAFLD is now called metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH is now metabolic dysfunction-associated steatohepatitis (MASH). Diagnosis requires at least one cardiometabolic risk factor.

### NAFLD Activity Score (NAS)

The NAS is a composite score evaluating steatosis (0-3, based on percentage of hepatocytes involved), lobular inflammation (0-3, based on foci per 20x field), and hepatocyte ballooning (0-2). A NAS of 5 or greater correlates with MASH while a NAS below 3 generally excludes it. However, the NAS is a research tool and should not substitute for the pathologic diagnosis of steatohepatitis.

### Steatohepatitis Histologic Features

The diagnosis of steatohepatitis requires macrovesicular steatosis as a prerequisite, combined with hepatocyte ballooning (enlarged, pale, swollen hepatocytes with loss of cytoplasmic detail that may contain Mallory-Denk bodies, which are eosinophilic cytoplasmic inclusions positive for ubiquitin and p62/SQSTM1) and lobular inflammation (a mixed infiltrate of lymphocytes, neutrophils, and macrophages). The characteristic fibrosis pattern is perisinusoidal or pericellular ("chicken-wire" pattern), located in zone 3 in adults and zone 1 in children.

### Fibrosis Staging (NASH CRN)

Stage 0 has no fibrosis. Stage 1 shows perisinusoidal or periportal fibrosis (subdivided into 1a for mild zone 3, 1b for moderate zone 3, and 1c for portal/periportal only). Stage 2 combines perisinusoidal and portal/periportal fibrosis. Stage 3 represents bridging fibrosis. Stage 4 is cirrhosis.

## Viral Hepatitis

### Chronic Hepatitis B

Chronic hepatitis B produces portal chronic inflammation with interface hepatitis. Ground-glass hepatocytes, which have abundant smooth endoplasmic reticulum containing HBsAg producing an eosinophilic granular cytoplasm, are characteristic. Sanded nuclei result from HBcAg accumulation. Immunohistochemistry for HBsAg (cytoplasmic) and HBcAg (nuclear and cytoplasmic) confirms the diagnosis. Fibrosing cholestatic hepatitis is a severe form of post-transplant recurrence characterized by periportal ductular reaction and cholestasis.

### Chronic Hepatitis C

Chronic hepatitis C characteristically produces portal lymphoid aggregates or follicles (suggestive but not pathognomonic), bile duct injury with lymphocytic infiltration of ducts, mild steatosis (especially with genotype 3), and variable interface hepatitis and lobular activity.

### Grading and Staging Systems

The Metavir system grades activity from A0 to A3 and stages fibrosis from F0 to F4. The Ishak/Modified HAI grades necroinflammatory activity from 0 to 18 and stages fibrosis from 0 to 6. The Batts-Ludwig system uses a simpler 0 to 4 scale for both grade and stage.

| System | Activity Grade Range | Fibrosis Stage Range | Notes |
|---|---|---|---|
| Metavir | A0–A3 | F0–F4 | Most widely used for HCV |
| Ishak (Modified HAI) | 0–18 | 0–6 | More granular, research use |
| Batts-Ludwig | 0–4 | 0–4 | Simplified |

| Metavir Fibrosis Stage | Description |
|---|---|
| F0 | No fibrosis |
| F1 | Portal fibrosis without septa |
| F2 | Portal fibrosis with few septa |
| F3 | Bridging fibrosis |
| F4 | Cirrhosis |

## Autoimmune Hepatitis (AIH)

Autoimmune hepatitis produces dense portal and periportal lymphoplasmacytic inflammation with prominent interface hepatitis featuring a plasma cell-rich infiltrate. Additional characteristic findings include emperipolesis (lymphocytes within hepatocyte cytoplasm), hepatocyte rosette formation (clusters of hepatocytes around a central lumen), and centrilobular necrosis (zone 3 pattern, especially in acute presentations). The absence of granulomas and significant bile duct injury helps distinguish AIH from overlap syndromes.

## Primary Biliary Cholangitis (PBC)

The hallmark lesion is non-suppurative destructive cholangitis (the florid duct lesion), featuring lymphocytic and granulomatous inflammation destroying interlobular bile ducts. Granulomas surrounding damaged bile ducts represent a pathognomonic early feature. The disease progresses through ductopenia to cholestasis. Anti-mitochondrial antibodies (AMA) are positive in over 90 percent of cases. Staging progresses through portal inflammation (Stage I), periportal fibrosis with ductular reaction (Stage II), bridging fibrosis (Stage III), and cirrhosis (Stage IV).

## Primary Sclerosing Cholangitis (PSC)

PSC is characterized by concentric periductal fibrosis ("onion-skinning") of interlobular bile ducts. Large duct PSC is diagnosed primarily by cholangiography showing beading of the bile ducts, while small duct PSC is diagnosed on biopsy showing characteristic periductal fibrosis. There is a strong association with ulcerative colitis (approximately 70 percent of cases) and an elevated risk of cholangiocarcinoma.

## Drug-Induced Liver Injury (DILI)

DILI has an extremely broad morphologic spectrum and can mimic almost any liver disease. Patterns include hepatocellular (zone 3 necrosis, hepatitis), cholestatic (bland cholestasis, ductular reaction), and mixed. Key features suggesting drug injury include prominent eosinophils in portal tracts, cholestasis disproportionate to inflammation, confluent necrosis, granulomas, and steatosis. Clinical correlation is essential, and DILI remains a diagnosis of exclusion.

<image>A medical illustration showing the major patterns of liver injury. Panel A (Hepatitic pattern): Portal tract with dense lymphocytic infiltrate extending beyond the limiting plate into periportal hepatocytes (interface hepatitis), lobular spotty necrosis, and acidophil bodies (apoptotic hepatocytes). Panel B (Cholestatic pattern): Hepatocanalicular cholestasis with bile plugs in dilated canaliculi (zone 3), ductular reaction at portal-periportal interface, and feathery degeneration of periportal hepatocytes. Panel C (Steatotic pattern): Macrovesicular steatosis with large lipid droplets displacing nuclei peripherally, ballooned hepatocytes with Mallory-Denk bodies, and pericellular/perisinusoidal fibrosis highlighted by trichrome stain. Panel D (Vascular pattern): Sinusoidal congestion and centrilobular hemorrhagic necrosis with dilated central vein, loss of centrilobular hepatocytes replaced by red blood cells.</image>

<image>A medical illustration of biliary liver diseases. Panel A (Primary biliary cholangitis - florid duct lesion): Interlobular bile duct surrounded by dense lymphocytic and granulomatous inflammation with epithelioid histiocytes, duct epithelial damage, and early ductular reaction. Panel B (Primary sclerosing cholangitis): Interlobular bile duct showing concentric periductal fibrosis (onion-skinning) with narrowed duct lumen, portal edema, and ductular reaction. Panel C (Large duct obstruction): Portal edema, periductal neutrophils, ductular reaction with bile-stained ductules, and periportal feathery degeneration. Panel D (Drug-induced cholestatic hepatitis): Bland hepatocanalicular cholestasis with prominent eosinophils in the portal infiltrate and mild ductular reaction.</image>

<image>A medical illustration of fibrosis staging in liver disease. Four panels showing progressive fibrosis using trichrome stain (blue collagen). Panel A (Stage 1 MASLD): Perisinusoidal/pericellular chicken-wire fibrosis in zone 3 surrounding individual hepatocytes. Panel B (Stage 2): Combined perisinusoidal and portal/periportal fibrosis. Panel C (Stage 3): Bridging fibrosis connecting portal tracts and central veins with fibrous septae. Panel D (Stage 4/Cirrhosis): Regenerative nodules of hepatocytes completely encircled by dense fibrous bands, with trichrome stain showing circumferential blue collagen. Reticulin stain inset showing thickened hepatocyte plates (>2 cells thick) within regenerative nodules.</image>

## Clinical Pearls

Hepatocyte ballooning is the histologic sine qua non of steatohepatitis; steatosis alone without ballooning does not constitute MASH/NASH regardless of the degree of fat accumulation. Ground-glass hepatocytes in chronic hepatitis B can be mimicked by drug-induced smooth ER proliferation (from barbiturates, for example) and fibrinogen storage disease; HBsAg immunohistochemistry confirms the diagnosis.

The florid duct lesion of PBC (granulomatous destruction of bile ducts) is pathognomonic but is only present in early disease. Later stages show ductopenia without the classic lesion, making liver biopsy less distinctive. Zone 3 (centrilobular) necroinflammation in the setting of autoimmune hepatitis can mimic drug-induced injury or acute viral hepatitis; the presence of a plasma cell-rich infiltrate and rosette formation helps distinguish AIH.

Fibrosis assessment by liver biopsy remains superior to non-invasive methods (FibroScan, FIB-4) for distinguishing intermediate fibrosis stages (F1 through F3), while non-invasive tools are most reliable for excluding cirrhosis or confirming the absence of significant fibrosis. When DILI is suspected, look for eosinophils in portal tracts, cholestasis without proportional hepatitis, and zone 3 necrosis; the clinical timeline correlation with drug exposure is often more diagnostic than histology alone.

## References
- Odze RD, Goldblum JR. *Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas*. 4th ed. Elsevier; 2023.
- Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41(6):1313-1321.
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*. 1996;24(2):289-293.
- Ishak K, et al. Histological grading and staging of chronic hepatitis. *J Hepatol*. 1995;22(6):696-699.
- Torbenson MS. *Liver Pathology*. Demos Medical; 2014.